Correction to: Risk scores to predict HCC and the benefits of antiviral therapy for CHB patients in gray zone of treatment guidelines

Wei Teng; Ting‑Tsung Chang; Hwai‑I Yang; Cheng‑Yuan Peng; Chien‑Wei Su; Tung‑Hung Su; Tsung‑Hui Hu; Ming‑Lung Yu; Hung‑Chih Yang; Jaw‑Ching Wu

doi:10.1007/s12072-023-10634-6

Correction to: Risk scores to predict HCC and the benefits of antiviral therapy for CHB patients in gray zone of treatment guidelines

Wei Teng
, Ting‑Tsung Chang
, Hwai‑I Yang
, Cheng‑Yuan Peng
, Chien‑Wei Su
, Tung‑Hung Su
, Tsung‑Hui Hu
, Ming‑Lung Yu
, Hung‑Chih Yang
, Jaw‑Ching Wu^*

^*此作品的通信作者

National Yang Ming Chiao Tung University
Chang Gung Memorial Hospital
National Cheng Kung University
Academia Sinica - Genomics Research Center
China Medical University Taichung
Veterans General Hospital-Taipei
National Taiwan University
Kaohsiung Medical University

研究成果: 期刊稿件 › 評論/辯論

摘要

Authors would like to add below funding information to their publication. This study was supported by funding from Ministry of Science and Technology (National Science and Technology Council) (104-2314-B-182A-048-MY3; 110-2314-B-A49A-505; 110-2314-B-075-010-MY3), VGHUST Joint Research Program, Tsou Foundation (VGHUST110-G7-3-3), VGHTPE Research Program (V107C-161, V108C-059 and V109C-049), Ministry of Health and Welfare (MOHW107-TDU-B-211-114019; 108-TDU-B-211-124019; 109-TDU-B-211-134019; 110-TDU-B-211-144019) and Cancer Progression Research Center, National Yang-Ming University from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education. The original article has been corrected.

原文	英語
頁（從 - 到）	1066
頁數	1
期刊	Hepatology International
卷	18
發行號	3
DOIs	https://doi.org/10.1007/s12072-023-10634-6
出版狀態	已出版 - 06 2024
對外發佈	是

文獻附註

Publisher Copyright:
© Asian Pacific Association for the Study of the Liver 2024.

UN SDG

此研究成果有助於以下永續發展目標

SDG3 健康與福祉

存取文件

10.1007/s12072-023-10634-6

其它文件與鏈接

Link to publication in Scopus

引用此

@article{0a55301c660543ffb5d3bd5047acf3ac,

title = "Correction to: Risk scores to predict HCC and the benefits of antiviral therapy for CHB patients in gray zone of treatment guidelines",

abstract = "Authors would like to add below funding information to their publication. This study was supported by funding from Ministry of Science and Technology (National Science and Technology Council) (104-2314-B-182A-048-MY3; 110-2314-B-A49A-505; 110-2314-B-075-010-MY3), VGHUST Joint Research Program, Tsou Foundation (VGHUST110-G7-3-3), VGHTPE Research Program (V107C-161, V108C-059 and V109C-049), Ministry of Health and Welfare (MOHW107-TDU-B-211-114019; 108-TDU-B-211-124019; 109-TDU-B-211-134019; 110-TDU-B-211-144019) and Cancer Progression Research Center, National Yang-Ming University from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education. The original article has been corrected.",

author = "Wei Teng and Ting‑Tsung Chang and Hwai‑I Yang and Cheng‑Yuan Peng and Chien‑Wei Su and Tung‑Hung Su and Tsung‑Hui Hu and Ming‑Lung Yu and Hung‑Chih Yang and Jaw‑Ching Wu",

note = "Publisher Copyright: {\textcopyright} Asian Pacific Association for the Study of the Liver 2024.",

year = "2024",

month = jun,

doi = "10.1007/s12072-023-10634-6",

language = "英语",

volume = "18",

pages = "1066",

journal = "Hepatology International",

issn = "1936-0533",

publisher = "Springer",

number = "3",

}

TY - JOUR

T1 - Correction to

T2 - Risk scores to predict HCC and the benefits of antiviral therapy for CHB patients in gray zone of treatment guidelines

AU - Teng, Wei

AU - Chang, Ting‑Tsung

AU - Yang, Hwai‑I

AU - Peng, Cheng‑Yuan

AU - Su, Chien‑Wei

AU - Su, Tung‑Hung

AU - Hu, Tsung‑Hui

AU - Yu, Ming‑Lung

AU - Yang, Hung‑Chih

AU - Wu, Jaw‑Ching

PY - 2024/6

Y1 - 2024/6

N2 - Authors would like to add below funding information to their publication. This study was supported by funding from Ministry of Science and Technology (National Science and Technology Council) (104-2314-B-182A-048-MY3; 110-2314-B-A49A-505; 110-2314-B-075-010-MY3), VGHUST Joint Research Program, Tsou Foundation (VGHUST110-G7-3-3), VGHTPE Research Program (V107C-161, V108C-059 and V109C-049), Ministry of Health and Welfare (MOHW107-TDU-B-211-114019; 108-TDU-B-211-124019; 109-TDU-B-211-134019; 110-TDU-B-211-144019) and Cancer Progression Research Center, National Yang-Ming University from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education. The original article has been corrected.

AB - Authors would like to add below funding information to their publication. This study was supported by funding from Ministry of Science and Technology (National Science and Technology Council) (104-2314-B-182A-048-MY3; 110-2314-B-A49A-505; 110-2314-B-075-010-MY3), VGHUST Joint Research Program, Tsou Foundation (VGHUST110-G7-3-3), VGHTPE Research Program (V107C-161, V108C-059 and V109C-049), Ministry of Health and Welfare (MOHW107-TDU-B-211-114019; 108-TDU-B-211-124019; 109-TDU-B-211-134019; 110-TDU-B-211-144019) and Cancer Progression Research Center, National Yang-Ming University from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education. The original article has been corrected.

UR - https://www.scopus.com/pages/publications/85182805291

U2 - 10.1007/s12072-023-10634-6

DO - 10.1007/s12072-023-10634-6

M3 - 评论/辩论

C2 - 38252366

AN - SCOPUS:85182805291

SN - 1936-0533

VL - 18

SP - 1066

JO - Hepatology International

JF - Hepatology International

IS - 3

ER -

Correction to: Risk scores to predict HCC and the benefits of antiviral therapy for CHB patients in gray zone of treatment guidelines

摘要

文獻附註

UN SDG

存取文件

其它文件與鏈接

指紋

引用此